Trial Profile
A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Apr 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Haemorrhage
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 15 Apr 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 07 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Mar 2015 according to ClinicalTrials.gov record.
- 07 Feb 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Mar 2015 according to ClinicalTrials.gov record.